<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730909</url>
  </required_header>
  <id_info>
    <org_study_id>Lactate_CBF</org_study_id>
    <nct_id>NCT03730909</nct_id>
  </id_info>
  <brief_title>The Effect Lactate Administration on Cerebral Blood Flow During Hypoglycemia</brief_title>
  <official_title>The Effect of Lactate Administration on Cerebral Blood Flow During Hypoglycemia; Are the Suppressive Effects of Lactate on Counterregulatory Responses to Hypoglycemia Reflected in an Altered CBF Response?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is thought that altered brain lactate handling is involved in the development of impaired
      awareness of hypoglycemia (IAH), i.e. the inability to timely detect hypoglycemia in people
      with type 1 diabetes (T1DM). Infusion of lactate diminishes symptomatic and hormonal
      responses to hypoglycemia in patients with normal awareness of hypoglycemia (NAH), resembling
      the situation of patients with IAH. It is unknown whether this attenuating effect is due to
      brain lactate oxidation or the result of lactate-induced alterations of global and regional
      cerebral blood flow (CBF).

      Normally, hypoglycemia causes a redistribution of CBF towards the thalamus, from where the
      sympathetic response to hypoglycemia is coordinated, but in IAH this effect is absent and
      global CBF is increased. We hypothesize that lactate infusion in patients with NAH will
      result in blunting of thalamic activation and/or enhanced global CBF. If so, these results
      may help delineating the pathogenesis of IAH which eventually creates new avenues to protect
      against the morbidity associated with hypoglycemia and IAH.

      Study design: Single-blind placebo controlled, randomized cross-over intervention study Study
      population: T1DM patients with NAH (n=10) Intervention: On two separate occasions, patients
      with T1DM and NAH will undergo a hyperinsulinemic euglycemic-hypoglycemic glucose clamp with
      or without the infusion of exogenous lactate. ASL-MRI will be applied to measure global and
      regional changes in CBF.

      Main study parameters/endpoints: The change in regional thalamic CBF in response to
      intravenous lactate infusion compared to placebo, during hypoglycemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2018</start_date>
  <completion_date type="Anticipated">June 11, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional CBF in ml/100g/min measured with ASL-MRI</measure>
    <time_frame>during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)</time_frame>
    <description>The change in regional thalamic CBF in response to intravenous lactate infusion compared to placebo, during hypoglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global CBF in ml/100g/min measured with ASL-MRI</measure>
    <time_frame>during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)</time_frame>
    <description>The change in global CBF in response to intravenous lactate infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counterregulatory hormone responses to hypoglycemia</measure>
    <time_frame>during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)</time_frame>
    <description>The difference in adrenaline (pmol/L) responses to hypoglycemia during lactate infusion compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom responses to hypoglycemia</measure>
    <time_frame>during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)</time_frame>
    <description>The difference in symptom responses to hypoglycemia (meausured with a validated questionnaire) during lactate infusion compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of metabolites in cell lysates or supernatants of the cultured immune cells</measure>
    <time_frame>during stable euglycemia (40 minutes) and hypoglycemia (45 minutes)</time_frame>
    <description>The effect of lactate administration on immune cell function and metabolism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Type1diabetes</condition>
  <condition>Hypoglycemia Unawareness</condition>
  <arm_group>
    <arm_group_label>Lactate infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>As a control condition, subjects will receive intravenous NaCl infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Lactate</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Lactate infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>NaCl infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes duration â‰¥ 1 year

          -  Age: 18-50 years

          -  Body-Mass Index: 18-30 kg/m2

          -  HbA1c: 42-75 mmol/mol (6-9%)

          -  Outcome Clarke questionnaire: 0-1

          -  Blood pressure: &lt;160/90 mmHg

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Use medication other than insulin, except for oral contraceptives or stable thyroxin
             supplementation therapy

          -  Presence of any other medical condition that might interfere with the study protocol,
             such as brain injuries, epilepsy, a major cardiovascular disease event or cardiac
             failure, known liver disease, anxiety disorders or a history of panic attacks.

          -  Microvascular complications of T1DM: Proliferative retinopathy, symptomatic diabetic
             neuropathy (including autonomic neuropathy) or Nephropathy; clinical/overt albuminuria
             or an estimated glomerular filtration rate &lt;60ml/min/1.73m2.

          -  MRI contraindications (pregnancy, severe claustrophobia, metal parts in body)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bastiaan de Galan, PhD</last_name>
    <phone>0243613286</phone>
    <email>bastiaan.degalan@radboud.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radoud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bastiaan de Galan, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

